Clinical Trial Update: Omission of SLNB in Triple-negative and HER2-positive Breast Cancer Patients with RCR and PCR in the Breast After NAST [NA]

View source ↗

Summary

Clinical trial update on omitting sentinel lymph node biopsy in patients with triple-negative and HER2-positive breast cancer after neoadjuvant therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Snippet

Sponsor: Toralf Reimer, MD PhD | Conditions: Breast Cancer Female, Breast Cancer | NA | Status: ACTIVE_NOT_RECRUITING